Weight Management

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

This “refreshing alternative” to calorie restriction does not include calorie counting, yet it is naturally associated with greater energy restriction compared to the latter.

Semaglutide was found to be the most effective drug for weight loss, but the benefits may not outweigh the cost associated with treatment.

Long lasting weight reduction was reported in individuals that were treated with tirzepatide with diet and exercise, compared to placebo.

Latinx teens suffering with mental health issues are at risk of developing cardiovascular conditions in their future.

Obesity is a chronic disease comprised of dysregulated adipose tissue, increasing the risk of developing serious health conditions, and requires more than just losing weight.

Poor sleep patterns were related to anxiety, depression, body fat gain, and loss of muscle mass in older individuals who are obese.

SYNCHRONIZE-1, SYCHRONIZE-2, SYNCHRONIZE-CVOT will evaluate survodutide for overweight and obesity.

Harmful LDL functionality contributes to an increase of cardiovascular disease in those with obesity but could decrease within weight loss.

Current federal statutes exclude anti-obesity medications for coverage when used for anorexia, weight loss, or weight gain.

Only 1% of children experienced obesity remission and lower socioeconomic status was connected to a worsened trajectory.

In addition to identifying strategies to reduce the adverse effects of sleep and circadian disruption, the study authors identify the impact of obesity on sleep.

As a once-daily oral treatment, orforglipron could help address barriers to injectable medications, such as semaglutide and liraglutide.

Although GLP-1 receptor agonists have shown promise in promoting weight loss, they are prescription medications and should be used under the guidance of health care professionals.

Beyond its primary role in diabetes treatment, SGLT-2 inhibitors have demonstrated versatility in various health aspects, offering benefits beyond glucose reduction.

After 1 year of treatment, semaglutide significantly improved physical function, which can improve quality of life outcomes and risk of death.

The phase 3 study will advance the safety findings of survodutide reported in the phase 2 study to aid overweight and obesity.

Consumerization of health care solutions is connected to a growing desire of patients to have accessible health care/health data and an individualized care experience.

Investigators aimed to determine whether liraglutide, an anti-obesity medication, could impact the learning process for individuals who had reduced insulin sensitivity due to obesity.

Most participants who received retatrutide lost a considerable amount of body weight; however, individual results varied given the diversity of obesity.

Guidelines from the American Academy of Pediatrics recommend treating obesity as a chronic illness.

Session at NACDS Total Store Expo discusses how pharmacies can leverage their accessibility to decrease diet-related diseases through health and wellness.

Despite the low uptake of healthy lifestyle behaviors to achieve 5% weight loss or greater, the probability of weight loss increased among individuals with higher initial BMI.

Individuals who restrict their eating to between 12 pm and 8 pm daily lost more weight than those who reduced overall calorie intake for type 2 diabetes.

A new study indicates that adults with obesity or who are overweight with weight-related comorbidities can help manage their weight with lifestyle changes in conjunction with specified treatment.

Consuming a vegetarian diet lowered LDL-C, HbA1C, and body weight when compared to a usual diet, but did not significantly affect systolic blood pressure levels.

Researchers recommend reducing soft drink consumption and increasing physical activity to begin minimizing this widespread issue.

Phenotype-based interventions are individualized treatment plans that consider genetic and phenotypic characteristics instead of general restricted eating or exercise management.

Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.